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B ACKGROUND  In the last decades, the interest for measuring the 
effects of mental disorders on daily functioning and on 
complex roles a person has to deal with, became 
higher.  
Among the mental disorders responsible for severe 
effects on social, family life, the major depressive epi-
sode (MDE) is one of the most impairing, and there is 
an increasing awareness that depression is a very com-
mon and very serious illness [1,2]. 
The World Health Organization (WHO) now ranks 
major depression as one of the most burdensome dis-
eases in the world [3]. 
Since 1994, the American Psychiatric Association introduced 
the Diagnostic and Statistical Manual of Mental Disorders, 
Fourth Edition (DSM-IV) system which emphasises the clini-
cal significance requirement for a diagnosis of Major Depres-
sive Disorder more prominently than did in the earlier DSM 
editions [4].  
 
T HE OBJECTIVES As in the last decades in Romania there was no nation-
ally representative population-based study available with re-
gard to DSM-IV disorders, from which the Major Depressive 
Episode (MDE) is one of most impairing, the objectives of 
the current article are to present some nationally representa-
tive estimates of lifetime, 12-months prevalence of MDE the 
age of onset, years in episode, the effects of MDE on role 
impairment.   
 
D IAGNOSTIC ASSESSMENT The DSM-IV criteria were used here and the target of 
the article is the major depressive episode , part of mood 
disorders.  
In addition to the prevalence of MDE, in this article is 
too reported the comorbidity with anxiety disorders 
(panic disorder, agoraphobia without panic, social anxi-
ety disorder, specific phobia, generalized anxiety disor-
der, adult separation anxiety disorder and posttraumatic 
stress disorder), substance use disorders, (alcohol and 
drug abuse and dependence) and impulse control disor-
ders [5,6,7]. 
 
D ESIGN AND SETTING The nationally representative “face-to face” household 
survey conducted in Romania between 2005-2007 used 
World Health Organization (WHO) World Mental Health 
(WMH) Survey Initiative version of the Composite Interna-
tional Diagnostic Interview (CIDI) [8,9].  
 
The fully structured interview  known as WMH-CIDI was 
administered by trained lay interviewers as Computer As-
sisted Personal Interview (CAPI version) [10].  
 
The interviewers explained the study and obtained ver-
bal informed consent prior to beginning each interview. 
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The objectives of the current article are to present some nationally 
representative estimates of lifetime, 12-months prevalence of MDE the age of 
onset, years in episode, the effects of MDE on role impairment.  
The lifetime prevalence of MDE was 3.3% for “all ages”, with higher 
values for females than for males (4.1% versus 2.5%) and the prevalence 
estimates of CIDI/DSM-IV 12-months Major Depressive Episode (MDE) was 
1.8% (2.2% for females and 1.4% for males).   
Approximately half of those with lifetime prevalence MDE presented 12-
months MDE too (53.8%).   
Within the age groups “18-34”, “all ages” and “50-64”, the females 
have the mean onset of MDE earlier than males (a slight difference for the 
first two situations, a difference of about 8 years for the latter). Within the 
age groups “35-49” of “65 years and over”, the males have the onset of MDE 
earlier than the females with 3-4 years.  
Regarding the mean number of years in episode, for all subjects was 
found a value of 5.7 years.  
Symptom severity assessed with the Quick Inventory of Depressive 
Symptomatology Self Report (QIDS-SR), revealed that almost two thirds of 
cases with MDE were “severe” or “very severe” from clinical point of view.  
Number of weeks depressed in the 365 days before the interview, expressed as 
mean was 30.8 for those with “severe” symptoms/domain.  
In the past 30 days, the highest WHODAS score was for out of role 
domain (36.2), then for mobility (14.6).   
Regarding the number of days out of role in the last year due to 
depression, this was 82.1 for the age group “50-64” and 63.5 for those of “65 
years old and over”.   
Major Depression Episode is a seriously impairment condition.  
The severe consequences of the depression on functioning in labour and 
social areas call attention to the need for early diagnostic, proper treatment 
and intervention. 
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R ESULTS Life time prevalence of Major Depressive Episode 
(see Table 1) 
For “all ages” the lifetime prevalence of MDE was 3.3%, 
with higher values for females than for males (4.1% versus 
2.5%).  
These point values translated in absolute figures, taking into 
account the real population from 2007, would correspond to 
approximatelly to 574000 persons from which 209000 are 
men and 365000 females. 
The lifetime prevalence of MDE is increasing by age; from 
2.1-2.6% for “18-34” and “35-49” age groups, to 4.4-5.2% 
for “50-64” and “65 and over”. The lifetime prevalence of 
MDE is higher for females, the difference being of 1.6 per-
centage points.  
For females, the lifetime prevalence of MDE is increasing by 
age from 3.1-3.4% for “18-34” and “35-49” age groups, to 
4.6-5.8% for “50-64” and “65 years and over” age groups. 
For males, the lifetime prevalence of MDE is increasing from 
1.1-1.8% for “18-34” and “35-49” age groups to 4.2% for the 
older age groups.  
The gender difference is quite large for the age groups “18-
34”, “35-49”, “65 years old and over” and for “all 
ages” (being 2 percentage points for the first one and 1.6 per-
centage points for the next two categories and for “all ages”).  
For the age group “50-64”, the gender difference is less than 
half percentage point.   
For females of “all ages” the prevalence rate is 4.1%; as the 
age is increasing, the prevalence rate is increasing too.  
Compared to each corresponding previous age group, the 
rhythm of the increase is of 1.2 percentage points for the 
groups of age “50-64” and “65 years and over”; instead, 
the increase for the age group “35-49” compared to the 
youngest is only of 0.3 percentage point.  For females af-
ter 50 years old, the prevalence of MDE is ascendant, with 
a rhythm more consistent than in young ages.   
For males of “all ages”, the prevalence rate is 2.5%. The 
same pattern of rate increase by age can be noticed but the 
difference found across ages for males is much higher than 
that for females. For instance, for the group of “50-64” com-
pared to “35-49” the difference is 2.4 percentage points for 
males compared to difference of 1.2 percentage points for 
females). 
Again the age difference for males for the age group “35-49” 
compared to the youngest age group “18-34” is almost twice 
higher than that corresponding for females (0.7 compared to 
0.3).  
At age groups “50-64” and “65 years and over” the rates for 
males are equal (4.2%).  
 
For males, the age of “50-64” brings a much higher preva-
lence but the prevalence rate remains constant for the next 
age group, instead, the prevalence for females is increasing 
constantly over 50 years old.  
S AMPLE The Romanian Mental Health Study is a nationally repre-
sentative survey of Romanian-speaking household residents 
aged 18 years and older in Romania. 
 
P ARTICIPANTS:  The sample contains 2357 subjects of 18 years or older, 
from which 940 cases are 44 years old or less. The response 
rate was 70.9%. 
 
M ETHODS: Were estimated the lifetime, 12-months prevalence, 
the mean and median age of onset, the median and the mean 
number of years in episode.  
The respondents who met CIDI/DSM-IV 12-months Major 
Depression Episode (MDE) was administered two scales: the 
Sheehan Disability Scale (SDS) [11] to assess the extent to 
which depression interfered with functioning in work, house-
hold, relationship, and social roles in the worst month of the 
past year and a truncated version of the Quick Inventory of 
Depressive Symptomatology Self Report (QIDS-SR) to as-
sess symptom severity in the worst month of the past year 
[12,13,14]. 
 
Transformation rules developed for QIDS-SR were used to 
convert scores into clinical severity categories mapped to the 
conventional Hamilton Rating Scale of Depression (HRSD) 
ranges of “none” (i.e. not clinically depressed), “mild”, 
“moderate”, “severe” and “very severe” [13,14]. 
 
In addition, an open-ended question asked respondents to 
estimate the number of days in the past 365 days when they 
were “totally unable to work or carry out the normal activities 
because of depression” [5,14]. 
 
All respondents completed the WHO Disability Assessment 
Schedule (WHO-DAS) [15] to assess functional impairments 
in 6 domains during the past 30 days: the domain 1 refers to the 
number of days in the past 30 days when the respondent was 
completely unable to work or carry out the normal activities 
because of physical or mental health problems and the domains 
from 2 to 6 refer to the severity, persistence of impairments in 5 
domains of functioning during the same period of time.   
 
These domains include: self-care (e.g., bathing, dressing), 
mobility (e.g., standing, walking), cognition (e.g., concen-
trating, remembering), social functioning (e.g., conversing, 
maintaining emotional control while around others), and 
role functioning (e.g., quality and quantity of normal ac-
tivities at home or work).  
 
All 6 WHO-DAS scales were transformed to a theoretical 
range of “0” meaning “no impairment at any time in the past 
30 days” to 1.0 meaning “complete inability to perform the 
functions throughout the full 30 days” [15]. 
 
Whenever possible were tested the difference in prevalence 
and Odds Ratios (ORs) across the age groups and between 
genders [5].  
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When both genders are considered together, we see a continu-
ous increase, from one age group to another.  
A substantial increase can be noticed after 50 years old com-
pared with the age “35-49” (1.8 percent increase).  
After the age of 65 years, even not so ascendant (0.8 percentage 
points), the increasing tendency still can be noticed.   
The lowest increase can be seen for the age group “35-
49” compared to the youngest (0.5 percentage points).  
The lifetime of MDE has a significant difference across age 
groups for males and for “all subjects” but not for females.  
For “all subjects” with lifetime MDE there is a significant 
difference across genders but this cannot be found within 
each age group.  
 
The mean age of MDE onset (see table 2)  
For “all subjects”, the mean age of onset is 32 years, rang-
ing shortly from 31.1 for females to 33.5  
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Table 1. Prevalence of life-time and 12-months MDE 
  Total Females Males   
Diagnosis 
(12 Mo or 
LT) 
Cohorts Denominator N1 N
2 %(SE) Denominator N1 N
2 %(SE) Denominator N1 N
2 %(SE) 





























. . X²=2.2, P=.528, df=3 . . 
X²=1.0, 






























. . X²=8.4*, P=.039, df=3 . . 
X²=2.3, 
































. . X²=2.2, P=.535, df=3 . . 
X²=0.6, 





1Total cases among each age group    
2cases of 12-mo/LT MDE among the age groups    
33 df tests for significant difference across age groups and 1 df test for significance difference across genders; odds ratios and significance 
tests are not presented for the models where the size of the subsample is less than 15, or the count of the dependent variable is less than 5   
*The test is significant at the 0.05 level  
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It seems that in the most recent cohorts, so for the youngest, 
the onset of MDE is earlier compared to the eldest.  
 
The median age of onset (see table 2)  
Regarding the median age of onset, 50% of the persons with 
MDE had the onset before the age of 28.6 years.  
50% of the persons with lifetime MDE had the onset be-
fore the age of 18 years within the youngest age group 
(“18-34”) and before 25.3 years within the “35-49” age 
group. 
For the age group “50-64” and of “65 years and over”, the 
median age of onset was 31.9 years and respectively 34.6 
years. 
Regarding the inter quartile range (IQR), containing 50% of 
the distribution from the first till the third quartile, can be 
noticed that within the age group “18-34”, the age of onset of 
50% of the subjects happened from 17.3 till 21 years old, 
within a range of 4.3 years.  
Within the age group of “35-49”, 50% of the subjects had the 
age of onset from 20.6 till 32.6 years old within a range of 12 
years and within the next age group of “50-64”, for 50% the 
age of onset took place from 25.2 till 44.9 years old within a 
range of 19.7 years.  
for males; the age of onset is 2.4 years lower for females com-
pared to males, indicating an earlier onset.   
For the two first age groups the mean age of onset of MDE is 
21.1 and respectively 26.4 but is 35.3 and respectively 39.8 
for the eldest age groups.  
The gender difference shows slightly higher mean age of on-
set for males within the youngest age group (21.9 for males 
compared to 20.9 for females) and for “all ages” (33.5 for 
males compared to 31.1 for females) but consistently much 
higher for the age group “50-64” (39.8 for males and 31.5 for 
females).  
Within the age groups “18-34”, “all ages” and “50-64”, the 
females have the onset of MDE earlier than the males (a dif-
ference of 1-2.4 years for the first two situations, and of about 
8 years for the latter). 
Compared to females, the onset of MDE is earlier for the 
males belonging to the age group “35-49” (24.3 for males and 
27.4 for females) and for those of “65 years and over” (37 for 
males and respectively 41.3 for females).  
 
Within the age groups “35-49” of “65 years and over”, the 
males have the onset of MDE earlier than the females with 
3.1-4.3 years.  
RESEARCH 
29 
Management in health 
XIV/2/2010; pp. 26-35 
Table 2. History of depression by age and sex 
  Total Females Males   
  Cohorts N1 Mean(SE) Median (IQR Range) N
1 Mean(SE) Median (IQR Range) N
1 Mean(SE) Median (IQR Range) 






18-34 13 21.1 (1.5) 18.0 (17.3-21.0) 10 20.9 (1.6) 
18.2 
(17.3-21.1) 3 21.9 (3.2) 
18.0 
(18.0-21.0) --- 
35-49 15 26.4 (2.7) 25.3 (20.6-32.6) 11 27.4 (2.2) 
25.9 






50-64 33 35.3 (2.6) 31.9 (25.2-44.9) 20 31.5 (3.3) 
28.0 






65+ 40 39.8 (3.2) 34.6 (22.5-54.7) 27 41.3 (3.4) 
39.7 






All Ages 101 32.0 (1.7) 28.6 (19.3-42.2) 68 31.1 (1.9) 
26.4 










. X²=62.6*, P=.000, df=3   . 
X²=41.8*, 
P=.000, df=3   . 
X²=25.4*, 






18-34 13 2.1 (0.4) 1.2 (1.0-1.9) 10 2.2 (0.5) 
1.1 
(1.0-2.2) 3 1.8 (0.2) 
2.0 
(2.0-2.0) --- 
35-49 15 6.5 (1.8) 5.4 (6.0-8.3) 11 6.9 (2.3) 
4.7 






50-64 33 5.8 (1.1) 4.2 (2.0-7.7) 20 6.6 (1.0) 
6.6 






65+ 40 7.5 (1.6) 3.7 (1.2-11.5) 27 6.6 (1.5) 
3.0 






All Ages 101 5.7 (0.7) 2.7 (2.0-7.8) 68 5.6 (0.6) 
3.0 










. X²=18.0*, P=.000, df=3   . 
X²=25.2*, 
P=.000, df=3   . 
X²=13.2*, 
P=.004, df=3     
1Cases with lifetime MDE;    
23 df tests for significant difference across age groups and 1 df test for significance difference across genders; odds ratios and significance 
tests are not presented for the models where the size of the subsample is less than 15, or the count of the dependent variable is less than 5;   
Significance tests also omitted if dependent variable has no variation (all are 0s or all are 1s)  
Within the age group of those of “65 years and over”, the 
onset inter quartile range happened from 22.5 till 54.7 years 
within a range of 32.2 years.  
Considering “all ages”, 50% from the subjects had the onset 
from 19.3 till 42.2 years old within a range of 22.9 years.  
Across the age groups there is a significant difference for the 
mean age of onset for  “all subjects” and within each gender.  
By gender can be noticed a significant difference for the age 
group of “50-64”.  
 
The mean number of years in episode (see table 2) 
Regarding the mean number of years in episode, for all sub-
jects with lifetime MDE was found a value of 5.7 years.   
 
As the age is increasing, the mean number of years in episode 
gets higher: is 2.1 years for the youngest age group, reaches a 
three times higher value of 6.5 years for those of “35-49” 
years old; is decreasing slightly to 5.8 years for the “50-64” 
age group and is reaching 7.5 years for the eldest age group of 
“65 years and over”. 
It was found a quite big gender difference of 2.6 years for the 
eldest age group of those of “65 years and over” (6.6 for fe-
males and 9.2 years for males), the males appearing more 
affected regarding the time in MDE when they get older.  
For the age groups of “35-49” and “50-64”, the gender differ-
ence is reversed, the females showing a mean number of 
years in episode larger with 1-1.7 years than the men (6.9 
years for females and 5.9 years for males in the age group of 
“35-49” years old; 6.6 years for females and 4.9 years for 
males in the age group of “50-64” years old).  
For the youngest age group the mean number of years in epi-
sode is only slightly higher (0.4 years) for females than for 
male (2.2 for females and 1.8 for males). 
For mean years in episode, across age groups was found a 
significant difference for “all subjects” with 12-months MDE 
but too for each gender. 
 
The median number of years in episode (see table 2) 
Regarding the median number of years in episode, 50% of all 
cases with lifetime MDE spent less than 2.7 years in episode.  
For the youngest age group, the median was 1.2 years, in-
creased 4.5 times for the “35-49” age group, reaching a value 
of 5.4 years.  
For the following age group, “50-64”, it decreased with 1.2 
years, reaching the value of 4.2 years and continued to de-
crease slowly in the eldest age group reaching the value of 3.7 
years.  
Looking to the inter quartile range (IQR) can be noticed that 
50% of the subjects (from the first till the third quartile) from 
the youngest age group spent in episode from 1 till 1.9 years. 
In the age group of “35-49” the time range of being in episode 
for 50% of the subjects with lifetime MDE was much longer 
from 6 till 8.3 years.  
For the eldest age groups, IQR became larger, being 2-7.7 for 
those of “50-64” years and 1.2–11.5 years for those of “65 
years and over”.  
Regarding the time in episode, the subjects of “35-49” years 
appear as the most affected, IQR being high and homogene-
ous (6-8.3 years).   
If we assess the gender difference by age groups, we can no-
tice that the most affected are the males in age group of “35-
49” (the median number of years in episode is 9, with IQR 
from 7 till 9 years) and the females in the age group of “50-
64” years (the median number is 6.6 years and the IQR 6-7.9 
years).  
The gender difference is obvious for the age groups “35-49” 
and “65 years and over”, where the males are more affected.  
The women are more affected than men in the age group of 
“50-64”.  
 
12-months prevalence of MDE (see table 1) 
The prevalence estimates of CIDI/DSM-IV12-months MDE 
were 1.8% (2.2% for females and 1.4% for males).  
These point values altered in absolute figures, taking into 
account the real population from 2007, would correspond to 
approximately to 313000 persons from which 117000 are 
men and 196000 females. 
For females, across age groups, the 12 months MDE preva-
lence increased slightly: was 1.6% for “18-34” group, 2.2% 
for “35-49” group, 2.5% for “50-64” group, reached 2.7% for 
those of “65 years and over”.  
For males, for the first age group “18-34” the prevalence was 
1.1% - lower than that of females, of 1.6% - and decreased 
slightly till 0.9% for “35-49” age group; it reached the highest 
value  for those of “50-64” years (2.3%) and decreased till the 
value of 1.5% for those of “65 years and over”.  
When the adults males get from “35-49” to “50-64” age 
group the 12-months MDE prevalence increases with 1.4 
percentage points, being the most spectacular increase no-
ticed within 12-month MDE prevalence.  
For all subjects, the 12-months MDE prevalence increased 
continuously from the youngest age till the age group of “50-
64” years having the values of 1.3% for “18-34” age group, 
1.5% for “35-49” age group, 2.4% for “50-64” age group and 
decreased slightly for those of “65 years and over” reaching 
the value of 2.2% for the last age group.  
For females and for “all cases” can be noticed a continuous 
increase of 12-months MDE prevalence as age is increasing.  
The females, accordingly with the 12-months prevalence of 
MDE, become more depressed as the age is increasing but the 
increase is minor under 1 percentage point, being 0.6 for the 
age group of “35-49” compared to the youngest and only 0.2-
0.3 when about other age groups.   
For “all cases”, the increase was more pronounced (of 0.9 
percentage points) for the age group “50-64” compared to 
“35-49”; the age group of “65 years and over” had a  
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ity domains: “mild”, “moderate”, “severe” or “very severe”. 
Almost half of those with 12-months MDE (45.6%) met the 
clinical category “very severe”, one sixth (16.5%) “severe”, 
more than fourth (27.3%) “moderate” and one tenth (9.6%) 
“mild” clinical severity category.  
About two thirds of cases with 12-months MDE were 
“severe” or “very severe” from clinical point of view. 
Number of weeks depressed in the 365 days before the 
interview, expressed as mean was 18.0 weeks for “all 
cases” with 12-months MDE, but varied by symptom se-
verity, being 11.7 for those with “mild” severity, 15.7-
16.0 for those with “moderate” and “very severe” catego-
ries and 30.8 for those with “severe” symptoms/domain.  
The mean number of days totally unable to work or carry 
on usual activities because of depression in the 365 days 
prior to the interviews was 45.8 for all 45 respondents 
with MDE but varied progressively with symptom sever-
ity.  
The number of days out of role was less than 1 day for 
“mild” severity, was 5.8 days for “moderate” cases, increased 
almost 5 times for those with “severe” symptoms (28.1 days), 
and again increased 3 times for those with “very severe” 
symptoms (82.7 days).  
For role impairment the percent of those who reported 
“severe” or “very severe” impairment in at least one Shee-
han Disability Scale (SDS) role domain was considered. 
For co morbidity was considered the percent of those with 
two or more co morbid 12-months CIDI/DSM IV disorders.  
The percent of those who reported “severe” or “very se-
vere” impairment in at least one SDS role domain was 
about one fourth (21-25%) for those with “mild”, 
“moderate” or “severe” symptom severity but was 80.5% 
for those with “very severe” category and almost 50% 
(49.7%) for all cases.  
As co morbidity the percent of those with two or more co 
morbid 12-months CIDI/DSM-IV disorders was less than 
one fifth (17.5%) for all 45 cases; the highest percent of co 
morbid disorders is met among those with “very severe” 
symptoms (27.8%) less among those with “mild” (17.9%) 
and less than 10% for those in “moderate” and “severe” cate-
gory (8% and 4.4%).  
 
Thirty-Day Standardized Comparisons of Functional 
Impairment by the WHO-DAS among Respondents With 
vs, Without CIDI/DSM-IV Major Depressive Disorder 
(see table 4) 
All respondents completed the WHO Disability Assessment 
Schedule (WHO-DAS) [15] to assess functional impairments 
in 6 domains during the past 30 days. 
In the past 30 days, the highest score WHO-DAS was for 
“out of role” domain (36.2), then for “mobility” (14.6) being 
much lower for “self care” and “cognition” (each one 5.5) 
and for “social” domain (3.3). 
 
prevalence rate slightly lower (with 0.2 percentage points) 
than the previous age group.  
For males, the age group “50-64” shows a consistent increase 
of 1.4 percentage points in 12-months MDE prevalence rate 
compared to previous age groups.  
For the age groups “35-49” and “65 years and over”, a de-
crease compared to the previous age group can be noticed, 
more pronounced for the last age group (0.2 respectively 0.8 
percentage points).   
Neither across cohorts within each gender or between genders 
within each age group is noticed any statistic significant dif-
ference.   
 
12-months MDE among lifetime MDE (see table 1)  
Talking about “all ages” can be noticed that approximately 
half of those with lifetime MDE presented 12-months MDE 
as well (53.8%).  
 
Among those with lifetime MDE, in the younger age groups, 
12-months MDE is higher compared to elder age groups, 
varying from 64.4% to 42.5%.  
 
It appears that among those with lifetime MDE, the older 
have a lower likelihood to have too 12-months MDE.     
 
The percent of those with 12-months MDE among those with 
lifetime MDE decreased from 58.7% for the age group “35-
49”, to 53.3% for “50-64” age group but much more till two 
fourths (42.5%) for the eldest age group.  
The proportion of 12-months MDE among lifetime MDE 
cases was similar for both males and females for all subjects 
(53.4% for females and 54.6% for males) and for the age 
group “50-64” (54.4% for females and 54.2% for males), rep-
resenting about half of lifetime MDE.  
 
Within the age group “35-49”, the percentage of subjects with 
12-months MDE among those with lifetime MDE was higher 
for females compared to males (63.4 versus 48.8%); a similar 
situation of a higher percent of 12-months MDE among life-
time MDE was noticed for the age group of those of “65 
years and over” (46.6% for females and 34.7% for males).  
 
From the subjects with lifetime MDE in the youngest age 
group (“18-34”), the proportion of 12-months MDE cases 
was much larger for males (100%) compared to females 
(51.8%) but the few number of cases recommends caution in 
interpreting.  
 
Neither across age groups or between genders was found a 
significant difference for the 12-months MDE among lifetime 
MDE.  
 
Symptom severity and correlates of symptom severity of 
12-months CIDI/DSM-IV Major Depressive Episode (see 
table 3) 
Symptom severity was assessed with the Quick Inventory of 
Depressive Symptomatology Self Report (QIDS-SR), ex-
pressed by percent of people with one of the symptom sever-
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Global WHO-DAS score was 13.0 in the last 30 days, 4.3 in 
the past 12 months and 5.8 over 12 months ago compared to 
2.0 for those with no lifetime MDE.   
Comparisons of respondents with no lifetime history of MDE 
on the WHO-DAS dimensions provides additional of broad 
impairment associated with MDE [5].  
Recent MDE (within 30 days before the interview) is associ-
ated with statistically significant impairments in three WHO-
DAS domains compared with respondents who never met 
criteria for MDE (p=0.028 for out of role domain, p=0.057 for 
mobility and p=0.06 for global WHO-DAS).     
 
Role Impairment of 12-Months MDE by age and gender 
(see table 5) 
From 46 cases with 12-months MDE, 44 had a valid Sheehan 
score. Responses were scored with a “0-to-10” visual ana-
logue scale having response options labelled: “none”  ( s c o r e 
0), “mild” (score1-3), “moderate” (score 4-6), “severe” (score 
7-9), and “very severe” (score 10).  
Regarding the “global” role functioning, the most im-
paired, being in “severe” category appeared “all cases” and 
the males from the age group “35-49” (mean Sheehan 
score 7.3 respectively 8.8, at lower and upper limit of 
“severe category”) and the  
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Table 3. Distributions and correlates of symptom severity (Quick Inventory of Depressive Symptomatology Self-Report) 
of 12-month CIDI/DSM-IV Major Depressive Episode 




1 9.6 (4.3) 27.3 (7.9) 16.5 (6,3) 45.6 (7.1) 100.0(0.0) 
II, Correlates of 
symptom severity 
Mean (SE) 
Duration (mean)2 11.7(6.3) 15.7 (3.3) 30.8 (6.1) 16.0 (2.5) 18.0 (2.4) 
Days out of role (mean)3 0.8 (0.7) 5.8 (2.5) 28.1 (28.3) 82.7 (31.6) 45.8 (15.8) 
% (SE) 
Role impairment (%)4 21.0 (18.7) 23.0 (12.3) 25.3 (11.0) 80.5 (11.1) 49.7 (7.9) 
Comorbidity (%)5 17.9 (16.5) 8.0 (6.0) 4.4 (4.6) 27.8 (8.7) 17.5 (4.8) 
  (n)6 (5) (14) (9) (17) (45) 
1Percent of people with the symptom severity domain,  
2Number of weeks depressed in the 365 days before the interview, F3,25=1,2, p=0,3327  
3Number of days totally unable to work or carry on usual activities because of depression in the 365 days prior to the interviews, F3,25=5,7, p=0,0057 
4Percent who reported severe or very severe impairment in at least one SDS role domain, X²2=17,6, p=0,0017 
5Percent with two or more comorbid 12-month CIDI/DSM-IV disorders, X²3=231,7, p=0,0007 
6Number of cases with valid QIDS-SR scores within each severity domain; the QIDS-SR was self-administered in a respondent booklet that 
was collected at the end of the interview 
7Significance tests control for age, sex, marital status, and education 
Table 4. Thirty-Day Standardized Comparisons of Functional Impairment by the WHO-DAS Among Respondents With 
vs, Without CIDI/DSM-IV Major Depressive Episode  
  Recency of MDE, Mean Score (SE) (95% CI)   
  Past 30 day Past 12 Months >12 Months Ago No Lifetime MDE   
WHO-DAS 
Domains n=16 n=30 n=55 n=2256 F3,25 P-Value* 






95% CI=(5.3,7.4) 3.6 0.028 






95% CI=(0.3,1.0) 0.5 0.699 






95% CI=(1.6,2.4) 2.9 0.057 





0.5 (SE=0.1),  
95% CI=(0.2,0.8) 1.7 0.185 






95% CI=(0.1,0.6) 0.3 0.817 






95% CI=(1.6,2.3) 2.8 0.06 
Abbreviations: CIDI, Composite International Diagnostic Interview; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, Fourth 
edition; MDE, Major Depressive Episode; WHO-DAS, World Health Organization-Disability Assessment Schedule; 
*Significantly different from respondents with no lifetime MDE at the .05 level, 2-sided test; 
**Comparison across the 4 recency categories. 
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Table 5. Severity of MDE Mean Sheehan score by age and sex category 
  Total Females Males   
Sheehan Disability 
Scale Cohorts N
1 Mean(SE) N1 Mean(SE) N1 Mean(SE) 1 df test between gender2 
Mean Sheehan score, 
global 
18-34 7 4.8 (1.2) 5 4.7 (1.8) 2 5.1 (1.1) X²=0.0,  P=.839, df=1 
35-49 8 7.3 (1.0) 6 6.7 (1.3) 2 8.8 (0.0) X²=2.5,  P=.114, df=1 
50-64 14 6.9 (0.6) 8 7.5 (1.1) 6 6.2 (1.2) X²=0.4,  P=.515, df=1 
65+ 15 6.2 (1.0) 11 6.5 (1.2) 4 5.4 (2.2) X²=0.2,  P=.666, df=1 
All Ages 44 6.3 (0.5) 30 6.4 (0.7) 14 6.3 (0.9) X²=0.0,  P=.915, df=1 
3 df significance test across 
cohorts2 . 
X²=4.4,  
P=.221, df=3 . 
X²=2.3,  
P=.515, df=3 . 
X²=13.9*, 
P=.003, df=3 -- 
Mean Sheehan score, 
close relations 
18-34 7 3.7 (1.5) 5 4.6 (1.8) 2 1.9 (2.0) X²=1.0,  P=.307, df=1 
35-49 8 6.9 (1.0) 6 6.6 (1.4) 2 7.8 (0.0) X²=0.8,  P=.359, df=1 
50-64 14 4.2 (0.9) 8 6.0 (0.9) 6 2.2 (1.6) X²=3.5,  P=.060, df=1 
65+ 15 5.1 (1.2) 11 5.1 (1.6) 4 5.2 (2.2) X²=0.0,  P=.960, df=1 
All Ages 44 4.9 (0.7) 30 5.6 (0.7) 14 3.7 (1.3) X²=1.7,  P=.188, df=1 
3 df significance test across 
cohorts2 . 
X²=5.4,  
P=.148, df=3 . 
X²=1.4,  
P=.698, df=3 . 
X²=15.7*, 
P=.001, df=3 -- 
Mean Sheehan score, 
home 
18-34 7 3.7 (1.4) 5 3.0 (1.9) 2 5.1 (1.1) X²=0.9,  P=.339, df=1 
35-49 8 5.8 (1.1) 6 5.4 (1.4) 2 7.1 (0.0) X²=1.5,  P=.217, df=1 
50-64 14 6.1 (0.6) 8 6.5 (1.2) 6 5.6 (1.0) X²=0.2,  P=.629, df=1 
65+ 15 5.2 (0.9) 11 5.8 (0.9) 4 3.7 (2.3) X²=0.8,  P=.381, df=1 
All Ages 44 5.3 (0.4) 30 5.2 (0.7) 14 5.4 (0.8) X²=0.0,  P=.895, df=1 
3 df significance test across 
cohorts2 . 
X²=3.8,  
P=.283, df=3 . 
X²=2.5,  
P=.480, df=3 . 
X²=6.0,  
P=.113, df=3 -- 
Mean Sheehan score, 
work 
18-34 7 2.7 (1.5) 5 3.1 (2.0) 2 2.2 (2.2) X²=0.1,  P=.763, df=1 
35-49 8 6.0 (1.0) 6 5.5 (1.4) 2 7.1 (0.0) X²=1.3,  P=.253, df=1 
50-64 14 5.3 (1.2) 8 6.8 (1.0) 6 3.7 (2.3) X²=1.2,  P=.264, df=1 
65+ 15 4.8 (1.1) 11 4.6 (1.3) 4 5.4 (2.2) X²=0.1,  P=.771, df=1 
All Ages 44 4.8 (0.6) 30 5.1 (0.6) 14 4.3 (1.5) X²=0.2,  P=.657, df=1 
3 df significance test across 
cohorts2 . 
X²=3.6,  
P=.307, df=3 . 
X²=4.2,  
P=.240, df=3 . 
X²=5.6,  
P=.134, df=3 -- 
Mean Sheehan score, 
social 
18-34 7 2.7 (1.6) 5 3.2 (2.1) 2 1.6 (1.7) X²=0.3,  P=.554, df=1 
35-49 8 6.6 (1.3) 6 6.1 (1.7) 2 8.1 (0.0) X²=1.5,  P=.216, df=1 
50-64 14 4.7 (0.9) 8 6.5 (1.1) 6 2.7 (0.9) X²=6.8*,  P=.009, df=1 
65+ 15 5.0 (1.1) 11 5.8 (1.6) 4 2.8 (1.3) X²=2.0,  P=.160, df=1 
All Ages 44 4.7 (0.6) 30 5.5 (0.7) 14 3.4 (1.1) X²=2.3,  P=.128, df=1 
3 df significance test across 
cohorts2 . 
X²=5.5,  
P=.136, df=3 . 
X²=2.9,  
P=.414, df=3 . 
X²=65.0*, 
P=.000, df=3 -- 
Mean days out of role 
18-34 7 1.8 (0.8) 5 2.2 (1.0) 2 1.1 (1.1) X²=0.6,  P=.453, df=1 
35-49 8 20.5 (17.8) 6 28.0 (22.6) 2 0.0 (0.0) X²=1.5,  P=.214, df=1 
50-64 14 82.1 (51.6) 8 41.3 (37.8) 6 128.1 (94.3) X²=0.7,  P=.395, df=1 
65+ 14 63.5 (26.0) 10 60.7 (35.9) 4 70.1 (60.0) X²=0.0,  P=.906, df=1 
All Ages 43 45.3 (15.6) 29 33.4 (12.2) 14 66.8 (44.9) X²=0.4,  P=.515, df=1 
3 df significance test across 
cohorts2 . 
X²=13.7*,  
P=.003, df=3 . 
X²=6.8,  
P=.080, df=3 . 
X²=3.2,  
P=.356, df=3 -- 
1 Cases with a valid Sheehan severity score / # of days out of role, among those with 12-mo MDE;  
2 three df tests for significant difference across age groups and 1 df test for significance difference across genders; odds ratios and 
significance tests are not presented for the models where the size of the subsample is less than 15, or the count of the dependent variable is 
less than 5;   
Significance tests also omitted if dependent variable has no variation (all 0s or all 1s)  33 
females from the age group “50-64” (mean Sheehan score 
of 7.5). 
The tests for significant difference across age groups 
showed for males statistical significance (X²=13.9*, 
P=.003, df=3).  
Regarding the “close relationship” role, the most impaired 
appeared the males in the “35-49” age group (mean Sheehan 
score of 7.8 in severe category).  
The tests for difference significance across age groups 
showed for males statistical significance (X²=15.7*, P=.001, 
df=3).  
In “home” functioning role, the most impaired were the males 
of “35-49” age group (mean Sheehan score of 7.1 correspond-
ing to severe category).  
The tests for significant difference across age did not show 
statistical significance.  
Regarding the “work” role impairment the most impaired 
were the males of “35-49” age group, having a score in severe 
category at lower limit (score 7.1). 
No significant difference was found across ages and between 
genders.   
Regarding the “social” functioning role, the most impaired 
appeared the males of “35-49” age group (score 8.1 of severe 
impairment).   
The tests for significant difference across age groups showed 
statistical significance for males (X²=65.0*, P=.000, df=3) 
and the test for significant difference between genders 
showed statistical significance too for the age group “50-
64” (X²=6.8*, P=.009, df=1).  
Regarding “the days out of role”, if the youngest age group 
had 1.8 days out of role in the last year due to depression, this 
increased to 20.5 for those of “35-49”, to 82.1 for the age 
group “50-64” and 63.5 for those of “65 years old and over”.   
The significance test across cohorts showed significant differ-
ence (X²=13.7*, P=.003, df=3).  
 
C ONCLUSIONS  The prevalence of MDE was 3.3% for “all ages”, with 
higher values for females than for males (4.1% versus 2.5%).   
The lifetime prevalence of MDE is increasing by age groups 
for “all cases” with lifetime MDE and within each gender.   
A significant difference across age groups for males and for 
all subjects can be noticed, but not for females and across 
genders for all subjects with lifetime MDE but not within 
each age group.   
The prevalence estimates of CIDI/DSM-IV12-months Major 
Depressive Episode (MDE) was 1.8% (2.2% for females and 
1.4% for males).  
For females, within age groups, the 12-months MDE in-
creased slightly by age with less than 0.6 percentage point.  
When the adults males advance from “35-49” age group to 
“50-64” age group their 12-months MDE prevalence 
increases with 1.4 percentage points, being the most spec-
tacular increase noticed for 12-months MDE prevalence.  
If the 12-months MDE is continuously increasing by age for 
females, for males can be noticed two moments of slight de-
crease as age is increasing but too an relative important in-
crease.    
Approximately half (53.8%) of those with lifetime MDE pre-
sented 12-months MDE too.   
Among those with lifetime MDE, were more cases presenting 
12-months MDE in the younger age groups, compared to 
elder age groups, varying from 64.4% to 42.5%.  
Within the age groups “18-34”, “all ages” and “50-64”, the 
females have the mean onset of MDE earlier than males (only 
a slight difference for the first two situations, but a difference 
of about 8 years for the later).  
Within the age groups “35-49” of “65 years and over”, the 
males have the onset of MDE earlier than the females with 3-
4 years.  
Regarding the median age of onset, 50% of the persons with 
MDE had the onset before the age of 28.6 years.  
Regarding the mean number of years in episode, for “all 
cases” was found a value of 5.7 years (4.3-7.1).  
As the age is increasing, the mean numbers of years in epi-
sode get higher from 2.1 years for the youngest age group, till 
7.5 years for the eldest age group (“65 years and over”). 
The males appear more affected regarding the time in MDE 
when they get older.  
For the age groups of  “35-49” and “50-64”, the females 
show mean number of years in episode larger than the men 
(6.9 respectively 6.6 years for females versus 5.9  respec-
tively  4.9 years for males).  
Symptom severity assessed with the Quick Inventory of De-
pressive Symptomatology Self Report (QIDS-SR), revealed 
that almost two thirds of cases with MDE were “severe” or 
“very severe” from clinical point of view. 
Almost half of those with MDE (45.6%) met the clinical cate-
gory  “very severe”, one sixth  (16.5%) “severe”. 
Number of weeks depressed in the 365 days before the inter-
view, expressed as mean was 18.0 for all 45 respondents, but 
varied by symptom severity, being  15.7-16.0 for those with 
“moderate” and “very severe” categories and 30.8 for those 
with “severe” symptoms/domain.  
The mean number of “days totally unable to work or carry on 
usual activities because of depression” in the 365 days prior 
to the interviews was 45.8 for all 45 respondents with MDE 
but varied progressively with symptom severity from less 
than 1 day for “mild” severity, till 82.7 days for those with 
“very severe” symptoms.  
The percent of those who reported “severe” or “very severe” 
impairment in at least one SDS role domain was about was 
80.5% for those with “very severe” category and almost 50% 
(49.7%) for all cases.  
RESEARCH 
34 
Management in health 
XIV/2/2010; pp. 26-35 
(former Ministry of Health) with supplemental support of 
Eli Lilly Romania SRL. 
The highest percent of co morbid disorders is met among 
those with “very severe” symptoms (27.8%).  
All respondents completed the WHO Disability Assessment 
Schedule (WHO-DAS) to assess functional impairments in 6 
domains during the past 30 days: in the past 30 days, the high-
est score WHO-DAS was for out of role domain (36.2), then 
for mobility (14.6).   
Regarding the “global” role functioning, the most impaired, 
being in “severe” category appeared “all cases” and the males 
from the age group “35-49” (score 7.3, 8.8) and the females 
from the age group “50-64” (score of 7.5); for males was 
found significant difference across cohorts.   
Regarding the “close relationship”, the “home”, “work”, 
“social” functioning roles the most impaired appeared the 
males in the “35-49” age group with scores over 7 till 8.  
Regarding “the days out of role”, if the youngest age group 
had 1.8 days out of role in the last year due to depression, this 
increased to 20.5 for those of “35-49”, to 82.1 for the age 
group “50-64” and 63.5 for those of “65 years old and over”.   
Major Depression Episode is a seriously impairment condi-
tion:  nearly all respondents with 12-months MDE reported at 
least some role impairment associated with their depression in 
at least 1 of 4 Sheehan Disability Scale role domains.  
The severe consequences of the depression on functioning in 
labour and social areas call attention to the need for early di-
agnostic, proper treatment and intervention [5]. 
 
Acknowledgment 
The "Policies in Mental Health Area" and "National Study 
regarding Mental Health and Services Use" were carried 
out in conjunction with the World Health Organization 
World Mental Health (WMH) Survey Initiative. We thank 
the WMH staff for assistance with instrumentation, 
fieldwork, and data analysis. These activities were 
supported by the United States National Institute of Mental 
Health (R01MH070884), the John D. and Catherine T. 
MacArthur Foundation, the Pfizer Foundation, the US 
Public Health Service (R13-MH066849, R01-MH069864, 
and R01 DA016558), the Fogarty International Center
(FIRCA R03-TW006481), the Pan American Health 
Organization, the Eli Lilly & Company Foundation, Ortho-
McNeil Pharmaceutical, Inc., GlaxoSmithKline, Sanofi 
Aventis and Bristol-Myers Squibb. Acomplete list of 
WMH publications can be found at internet address:  
http://www.hcp.med.harvard.edu/wmh/ 
The Romania WMH study projects "Policies in Mental 
Health Area" and "National Study regarding Mental Health 
and Services Use" were carried out by the National School 
of Public Health & Health Services Management (former 
National Institute for Research & Development in Health), 
with technical support of Metro Media Transilvania, the 
National Institute of Statistics-National Centre for Training 
in Statistics, SC. Cheyenne Services SRL, Statistics 
Netherlands and were funded by Ministry of Public Health 
RESEARCH 
35 
Management in health 
XIV/2/2010; pp. 26-35 
References 
1. WELLS, K.B., STEWART, A., HAYS, R.D., et al.-The func-
tioning and well-being of depressed patients. JAMA., 262:914-
919, 1989. 
2. KOUZIS, A.C., EATON, W.W.- Emotional disability days: 
prevalence and predictors. Am J Public Health., 84:1304-1307, 
1994. 
3. World Health Organization. The World Health Report 2002- 
Reducing Risks, Promoting Healthy Life. Geneva, Switzerland: 
World Health Organization, 2002. 
4. American Psychiatric Association. Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition. Washington, DC: 
American Psychiatric Association, 1994. 
5. KESSLER, R.C.,  BERGLUND, P., DEMLER, O., JIN, R., KO-
RETZ, D., MERIKANGAS, K.R., RUSH, A.J., WALTERS, 
E.E, WANG, P.S.-The Epidemiology of Major Depressive Dis-
order Results from the National Comorbidity Survey Replication 
(NCS-R). JAMA, Vol 289, No. 23, June 2003. 
6. American Psychiatric Association, Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition, Text Revision 
(DSM-IV-TR), Washington, DC: American Psychiatric Associa-
tion, 2000. 
7. American Psychiatric Association, 2000, Diagnostic and statisti-
cal Manual of Mental Disorders, Fourth Edition, Text revision 
(DSM-IV, TR); Printed in Romanian by The Romanian Psychia-
trists Association, Bucharest, under Scientific Coordination of 
Prof. Dr. Aurel Romilă, 2000. 
8. KESSLER, R.C., USTUN, T.B.,- The World Mental Health 
(WMH) survey initiative version of the World Health Organiza-
tion (WHO) Composite International Diagnostic Interview 
(CIDI), Int J Methods Psychiatr Res., 13:93-121, 2004. 
9. KESSLER, R.C., WITTCHEN, H. U., ABELSON, J.M., et al.- 
Methodological studies of the Composite International Diagnos-
tic Interview (CIDI) in the US National Comorbidity Survey. Int. 
J Methods Psychiatr Res.,7:33-55, 1998. 
10.ROBINS, L.N., WING, J., WITTCHEN, H. U., et al.-The Com-
posite International Diagnostic Interview. Arch Gen Psychiatry. 
45:1069-1077, 1988. 
11.LEON, A.C., OLFSON, M., PORTERA, L., FARBER, L., 
SHEEHAN, D.V.- Assesing psychiatric impairment in primary 
care with the Sheehan Disability Scale. Int J Psychiatry Med., 
27:93-105, 1997. 
12.RUSH, A.J., GULLION, C..M., BASCO, M.R., JARRETT, 
R.B., TRIVEDI, M.H. -The Inventory of Depressive Symptoma-
tology (IDS). Psychol Med. 26:477-486, 1996. 
13.HAMILTON, M.- A rating scale for depression. J Neurol Neuro-
sur Psychiatry; 23., 1960. 
14.RUSH, A.J., TRIVEDI,  M.H., IBRAHIM, H.M., et al.- The 16-
item Quick Inventory of Depressive Symptomatology (QIDS), 
Clinician Rating (QIDS-C), and Self-Report (QIDS-SR): a psy-
chometric evaluation in patients with chronic major depression. 
Biol Psychiatry., 54:573-583, 2003. 
15.REHM, J., USTUN, T.B., SAXENA, S., et al.- On the develop-
ment and psychometric testing of the WHO screening instrument 
to assess disablement in the general population. Int J Methods 
Psychiatr Res., 8:110-123,1999. 
